NICE backs Akcea's Tegsedi; EMA restricts Lemtrada use while it probes safety concerns
→ UK’s NICE has endorsed the use of Akcea’s inotersen (branded as Tegsedi) to treat patients with a rare inherited condition called hereditary transthyretin-related amyloidosis (hATTR), after the Ionis $IONS sister company offered the agency an “improved commercial agreement.” This counts as a win for Akcea, which has been competing against Alnylam’s $ALNY Onpattro, although the dataset supporting its approval is seen as a runner up to Onpattro. The UK has roughly 150 hATTR patients, according to NICE.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.